Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
about
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry.5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.Validation of an isocratic HPLC method to detect 2-fluoro-beta-alanine for the analysis of dihydropyrimidine dehydrogenase activity.A predictive factor for the response to S-1 plus cisplatin in gastric cancer.Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.The impact of pharmacogenomics on gastrointestinal cancer therapy.Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysisDihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.A retrospective study on TS mRNA expression and prediction of the effects of adjuvant oral 5-fluorouracil in breast cancerGenetic factors influencing pyrimidine-antagonist chemotherapy.Characterization of dihydropyrimidine dehydrogenase in human colorectal tumoursCorrelation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridineUnfavourable expression of pharmacologic markers in mucinous colorectal cancer.A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracilPhase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupStem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use.Drug metabolism by tumours: its nature, relevance and therapeutic implications.Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.Conditioned media from human macrophages of M1 phenotype attenuate the cytotoxic effect of 5‑fluorouracil on the HT‑29 colon cancer cell line.Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.Synergistic effects of genetically engineered stem cells expressing cytosine deaminase and interferon-β via their tumor tropism to selectively target human hepatocarcinoma cells.Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer.Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors.Screening of lymph nodes metastasis associated lncRNAs in colorectal cancer patients.Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer.High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
P2860
Q30792328-B5ECF87D-6B15-4F61-B921-EC19A5B2CC77Q31098180-B035E0B6-E70B-4EB0-8B01-23A91B0EFD2BQ31149825-E4162BCE-B0E3-4397-B440-F0D58466FDA8Q33750445-3115BD8C-B185-4B00-ACA5-801D9BD051CEQ33884698-F05AE3EC-15E3-4F63-A5DE-83F452CAFB48Q33961798-013C7A7C-4682-4BD5-A892-8CE1A2F0CE1CQ33987641-BC27059E-A4C2-46BA-A259-C6BFEFF55656Q34155072-34FC116D-C4D8-44CB-836B-5AA1FC12E2D7Q34522413-ED5EB58C-1EFF-4754-B779-D4B4A78791BFQ34775315-4A25CB88-2D79-4360-ABEB-3DAD117BAA5EQ34837030-B18FF8FB-13F7-445C-84BD-9C8BC38AF58FQ35541901-08F66999-BA7B-4D9B-BCB2-3F51957B40BDQ35802542-04805900-98B1-44A1-A385-0BF49B3D2805Q36057115-2B3A94DA-F53B-49BD-B5CF-9ED186E25C89Q36116454-ECA17871-417B-4F3E-9D79-1EF396FC1576Q36142436-E694CB7A-ED0A-41AF-92FA-97EBFDA2000EQ36205831-EB55A110-8805-4C14-A86C-1F2747B3508DQ36295138-FAF1EC81-6507-48D9-980A-2A0118D20B23Q36474351-FD980A71-4D8B-4557-AFA2-74A791ED314DQ36616168-14041BE2-7939-45C1-A877-9D5DA6133C8FQ36619294-CC824E3A-1F86-48AA-88AE-17DD5E408099Q36621749-CC058395-D605-43AE-91D1-315D46BD0FCBQ36645679-CDA2AD87-03EC-440F-B436-5371D77AE8C5Q37008879-92B764B4-EDE6-439B-9AA9-640DFA82ECFAQ37279312-947B20FD-340A-4D59-87E1-63F2F3350EDAQ38260695-2E85E843-9352-4ACB-91DF-57A5AEAD63FDQ38948535-1B4BEC0F-568D-4203-B4E4-1674DAEDD20FQ38957071-1B80A826-9CD7-42C6-9279-0AA8CA7BDB33Q39315503-63B27FFE-4ED5-47C5-8E39-E9222D54AB12Q40388169-934829C5-1DA4-4790-B979-630716C2AA88Q41977175-D0BB3048-7AF6-4E0F-9CA7-24DA6FA3343BQ42057665-8CE15B31-8E92-4F65-B736-575B0567A560Q42263034-11305475-EC65-420B-B3CF-6C0A1EC12ABFQ42720542-05900493-AA65-44F9-886C-CB60FBEDC7B5Q43563145-03D3335D-CE08-40EF-9CE9-A41A2762E1C3Q43773484-F8BF1893-3247-41C5-9077-EBCCD31FFFD0Q43777035-07D7C8FA-E610-486E-A603-C9EB2AA829D0Q43846460-A9265544-F906-48AD-84EC-7398B1365489Q44063204-ABBC0D38-FCA2-4014-907F-2CC88322BEFCQ44159643-1B90439D-B1C2-4AEA-AE49-0C54AEA32A73
P2860
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Response to fluorouracil thera ...... midine dehydrogenase activity.
@en
Response to fluorouracil thera ...... midine dehydrogenase activity.
@nl
type
label
Response to fluorouracil thera ...... midine dehydrogenase activity.
@en
Response to fluorouracil thera ...... midine dehydrogenase activity.
@nl
prefLabel
Response to fluorouracil thera ...... midine dehydrogenase activity.
@en
Response to fluorouracil thera ...... midine dehydrogenase activity.
@nl
P2093
P1476
Response to fluorouracil thera ...... midine dehydrogenase activity.
@en
P2093
J L Fischel
M C Etienne
M Schneider
O Dassonville
P Formento
S Chéradame
P304
P356
10.1200/JCO.1995.13.7.1663
P407
P577
1995-07-01T00:00:00Z